Name: Infections Related to Biologics an Issue of Infectious Disease Clinics of North America (Volume 34-2) (The Clinics: Internal Medicine, Volume 34-2) (en Inglés)
Price: 139640.00 ARS
Availability: InStock
Author: Subramanian Aruna K.,Ho Dora
ISBN: 9780323733205

portada Infections Related to Biologics an Issue of Infectious Disease Clinics of North America (Volume 34-2) (The Clinics: Internal Medicine, Volume 34-2) (en Inglés)

Formato

Libro Físico

Editorial

Elsevier

Autor

Subramanian Aruna K.,Ho Dora

Idioma

Inglés

N° páginas

240

Encuadernación

Tapa Dura

ISBN13

9780323733205

Infections Related to Biologics an Issue of Infectious Disease Clinics of North America (Volume 34-2) (The Clinics: Internal Medicine, Volume 34-2) (en Inglés)

Subramanian Aruna K.,Ho Dora (Autor) · Elsevier · Tapa Dura

Libro Nuevo

$ 139.640

$ 174.550

Ahorras: $ 34.910

20% descuento

Envío normal

Origen: Reino Unido (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Martes 06 de Agosto y el Lunes 02 de Septiembre.

Lo recibirás en cualquier lugar de Argentina entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Infections Related to Biologics an Issue of Infectious Disease Clinics of North America (Volume 34-2) (The Clinics: Internal Medicine, Volume 34-2) (en Inglés)"

In collaboration with Consulting Editor Dr. Helen Boucher, Drs. Aruna Subramanian and Dora Yuk-Wai Ho have created an extremely timely and relevant issue for infectious disease physcians, as the field of biologics is exploding. These new agents are being used in rheumatologic diseases, hematologic malignancies, solid tumors, and other conditions; there is a lack of guidance in the literature on how to address their infectious risks. The first 9 articles explain the mechanisms of action of the biologic agents and the infectious disease risks associated with their immune system targets. The last few articles go into more depth on the viral, fungal, and mycobacterial infections that are potentiated by biologics, and discuss recommended prophylaxis and preventative strategies, including vaccinations. Specifically, articles are devoted to the following: TNF inhibitors; Agents targeting B cells; Agents targeting T cell activation; Direct T cell inhibition and agents targeting T cell migration and chemotaxis; IL-1 and IL-6 and other interleukin and IgE inhibition; Check-point inhibitors; Tyrosine kinase inhibitors for heme malignancies; EGFR inhibitors and other Tyrosine kinase inhibitors for solid tumors; Targeting JAK-STAT signaling and complement pathway for inflammatory diseases; Viral infections Potentiated by Biologics (and Prophylaxis); Endemic Fungal Infections Potentiated by Biologics (and prophylaxis); Mycobacterial Infections Potentiated by Biologics; and Vaccinations for patients on biologics. Readers will come away with the clinical overviews of these topics to improve prevention and management of patients treated with biologics.